Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1800 9
1801 5
1803 9
1811 11
1812 4
1899 1
1921 1
1940 1
1954 1
1958 1
1959 2
1962 1
1963 4
1964 2
1965 2
1971 1
1976 2
1978 1
1983 1
1986 1
1987 1
1989 5
1990 6
1991 9
1992 9
1993 17
1994 8
1995 11
1996 8
1997 10
1998 19
1999 11
2000 21
2001 21
2002 51
2003 45
2004 71
2005 95
2006 114
2007 137
2008 61
2009 56
2010 71
2011 46
2012 44
2013 40
2014 46
2015 33
2016 22
2017 18
2018 20
2019 30
2020 14
2021 23
2022 0
Text availability
Article attribute
Article type
Publication date

Similar articles for PMID: 17699476

1,160 results
Results by year
Filters applied: . Clear all
Page 1
Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
Sulowicz W, Locatelli F, Ryckelynck JP, Balla J, Csiky B, Harris K, Ehrhard P, Beyer U; PROTOS Study Investigators. Sulowicz W, et al. Clin J Am Soc Nephrol. 2007 Jul;2(4):637-46. doi: 10.2215/CJN.03631006. Epub 2007 May 23. Clin J Am Soc Nephrol. 2007. PMID: 17699476 Free article. Clinical Trial.
Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial.
Klinger M, Arias M, Vargemezis V, Besarab A, Sulowicz W, Gerntholtz T, Ciechanowski K, Dougherty FC, Beyer U. Klinger M, et al. Am J Kidney Dis. 2007 Dec;50(6):989-1000. doi: 10.1053/j.ajkd.2007.08.013. Am J Kidney Dis. 2007. PMID: 18037099 Clinical Trial.
Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
Besarab A, Salifu MO, Lunde NM, Bansal V, Fishbane S, Dougherty FC, Beyer U; Ba16285 Study Investigators. Besarab A, et al. Clin Ther. 2007 Apr;29(4):626-39. doi: 10.1016/j.clinthera.2007.04.014. Clin Ther. 2007. PMID: 17617286 Clinical Trial.
The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.
Provenzano R, Besarab A, Macdougall IC, Ellison DH, Maxwell AP, Sulowicz W, Klinger M, Rutkowski B, Correa-Rotter R, Dougherty FC; BA 16528 Study Investigators. Provenzano R, et al. Clin Nephrol. 2007 May;67(5):306-17. Clin Nephrol. 2007. PMID: 17542340 Clinical Trial.
1,160 results